FR15C0073I1 - - Google Patents

Info

Publication number
FR15C0073I1
FR15C0073I1 FR15C0073C FR15C0073I1 FR 15C0073 I1 FR15C0073 I1 FR 15C0073I1 FR 15C0073 C FR15C0073 C FR 15C0073C FR 15C0073 I1 FR15C0073 I1 FR 15C0073I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR15C0073(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR15C0073I1 publication Critical patent/FR15C0073I1/fr
Application filed filed Critical
Application granted granted Critical
Publication of FR15C0073I2 publication Critical patent/FR15C0073I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR15C0073C 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti) Active FR15C0073I2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275 2003-09-03
EP03103319 2003-09-08
EP03103335 2003-09-10
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors
EP04787096.9A EP1663240B2 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Publications (2)

Publication Number Publication Date
FR15C0073I1 true FR15C0073I1 (enrdf_load_stackoverflow) 2015-04-12
FR15C0073I2 FR15C0073I2 (fr) 2016-02-12

Family

ID=34280181

Family Applications (5)

Application Number Title Priority Date Filing Date
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0073C Active FR15C0073I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR15C0072C Active FR15C0072I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1024C Active FR16C1024I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1022C Active FR16C1022I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR15C0071C Active FR15C0071I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Family Applications After (3)

Application Number Title Priority Date Filing Date
FR15C0072C Active FR15C0072I2 (fr) 2003-09-03 2015-10-21 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1024C Active FR16C1024I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)
FR16C1022C Active FR16C1022I1 (fr) 2003-09-03 2016-12-20 Combinaison d'un inhibiteur non-nucleosidique de la transcriptase inverse (nnrti) contenant une pyrimidine avec un inhibiteur nucleosidique de la transcriptase inverse (nrti)

Country Status (24)

Country Link
US (9) US20080200435A1 (enrdf_load_stackoverflow)
EP (1) EP1663240B2 (enrdf_load_stackoverflow)
JP (3) JP5507791B2 (enrdf_load_stackoverflow)
KR (1) KR20060090658A (enrdf_load_stackoverflow)
CN (1) CN101060844B (enrdf_load_stackoverflow)
AP (1) AP2109A (enrdf_load_stackoverflow)
AU (5) AU2004268390B2 (enrdf_load_stackoverflow)
BE (1) BE2015C053I2 (enrdf_load_stackoverflow)
CA (1) CA2537095C (enrdf_load_stackoverflow)
CY (5) CY2015039I2 (enrdf_load_stackoverflow)
FI (1) FI1663240T4 (enrdf_load_stackoverflow)
FR (5) FR15C0071I2 (enrdf_load_stackoverflow)
HR (1) HRP20150798T4 (enrdf_load_stackoverflow)
HU (5) HUS1500053I1 (enrdf_load_stackoverflow)
IL (2) IL173438A (enrdf_load_stackoverflow)
LT (2) LTPA2016045I1 (enrdf_load_stackoverflow)
LU (3) LU92853I2 (enrdf_load_stackoverflow)
MX (1) MXPA06002437A (enrdf_load_stackoverflow)
MY (1) MY169670A (enrdf_load_stackoverflow)
NL (2) NL300781I1 (enrdf_load_stackoverflow)
NO (6) NO334877B1 (enrdf_load_stackoverflow)
NZ (1) NZ545306A (enrdf_load_stackoverflow)
PL (1) PL1663240T5 (enrdf_load_stackoverflow)
WO (1) WO2005021001A1 (enrdf_load_stackoverflow)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
CA2686429C (en) 2002-08-09 2010-11-16 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
CA2577288C (en) * 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
KR101276571B1 (ko) * 2004-09-02 2013-06-18 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 푸마레이트
CN101068597B (zh) * 2004-09-02 2012-04-18 詹森药业有限公司 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
MX2007002595A (es) * 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Clorhidrato de 4-[[4-[[4- (2-cianoetenil)-2, 6-dimetilfenil] amino]-2- pirimidinil] amino] benzonitrilo.
HRP20120499T1 (hr) * 2004-09-02 2012-07-31 Janssen@Pharmaceutica@NV Fumarat cijanoetenil dimetilfenil amino pirimidinil amino benzonitrila
TWI457136B (zh) * 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CA2633603C (en) * 2005-12-14 2016-09-13 Cipla Limited Pharmaceutical combination
WO2007082922A2 (en) * 2006-01-20 2007-07-26 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tcm278
US9044509B2 (en) * 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
ES2573641T3 (es) 2008-01-03 2016-06-09 Université D'aix-Marseille Triterapia utilizable para el tratamiento de un paciente infectado por VIH
MY160360A (en) * 2008-12-24 2017-02-28 Janssen Sciences Ireland Uc Implantable devices for treating hiv
MX2012007210A (es) 2009-12-21 2012-07-23 Janssen R & D Ireland Implante removible degradable para la liberacion sostenida de un compuesto activo.
HUE026849T2 (en) 2010-01-27 2016-08-29 Viiv Healthcare Company Corp Service Company Therapeutic combination containing dolutegravir, abacavir and lamivudine
RS53691B1 (en) * 2010-11-19 2015-04-30 Janssen R&D Ireland THERAPEUTIC COMPOSITIONS CONTAINING RILPIVIRINE HCL AND TENOVOFIR DIZOPROXYL FUMARATE
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
CA2848631C (en) * 2011-09-16 2019-10-01 Hetero Research Foundation Rilpivirine hydrochloride
WO2014100323A1 (en) 2012-12-21 2014-06-26 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN113546052A (zh) 2015-11-09 2021-10-26 吉利德科学公司 治疗人免疫缺陷病毒的治疗组合物
US11065198B2 (en) 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
US11234981B2 (en) 2017-04-18 2022-02-01 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS
AU2020391004A1 (en) 2019-11-29 2022-04-07 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
JPH07112975B1 (enrdf_load_stackoverflow) 1990-07-19 1995-12-06 Otsuka Pharma Co Ltd
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0610441A4 (en) * 1991-10-29 1996-01-10 Clover Cons Ltd CROSSLINKABLE POLYSACCHARIDES, POLYCATIONS AND LIPIDS CAN BE USED TO ENCODE AND DISPENSE MEDICINAL PRODUCTS.
WO1993023021A2 (en) 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) * 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
ATE296091T1 (de) 1999-09-21 2005-06-15 Skyepharma Canada Inc Oberflächenmodifizierte teilchenförmige zusammensetzungen biologisch aktiver stoffe
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TW200800298A (en) * 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
AU2001249591A1 (en) 2000-03-30 2001-10-15 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
HUP0401811A2 (hu) 2000-12-11 2004-12-28 Takeda Chemical Industries, Ltd. Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
CA2686429C (en) 2002-08-09 2010-11-16 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7497855B2 (en) * 2002-09-04 2009-03-03 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
WO2004043433A2 (en) 2002-11-08 2004-05-27 Glaxo Group Limited Pharmaceutical antiviral compositions
BR0316209A (pt) 2002-11-15 2005-09-27 Tibotec Pharm Ltd Indolpiridìnio substituìdo como compostos antiinfecciosos
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
MXPA05008364A (es) 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevencion de una infeccion por vih.
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
MXPA06014253A (es) 2004-06-08 2007-07-13 Vertex Pharma Composiciones farmaceuticas.
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
MX2007002595A (es) 2004-09-02 2007-04-25 Janssen Pharmaceutica Nv Clorhidrato de 4-[[4-[[4- (2-cianoetenil)-2, 6-dimetilfenil] amino]-2- pirimidinil] amino] benzonitrilo.
CA2577288C (en) 2004-09-02 2010-11-30 Janssen Pharmaceutica N.V. Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
KR101290115B1 (ko) 2004-11-16 2013-07-29 엘커메스 파마 아일랜드 리미티드 주사가능한 나노입자형 올란자핀 제형
TWI457136B (zh) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
US20060269475A1 (en) * 2005-04-11 2006-11-30 Ryu Wonhyoung Multi-layer structure having a predetermined layer pattern including an agent
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
JP5243247B2 (ja) 2005-07-28 2013-07-24 アイエスピー インヴェストメンツ インコーポレイテッド スプレー乾燥された粉体及び粒状化された材料の特性の改良方法、並びにそれによって製造した製品
WO2007082922A2 (en) 2006-01-20 2007-07-26 Tibotec Pharmaceuticals Ltd. Long term treatment of hiv- infection with tcm278
SI2040671T1 (en) 2006-06-23 2018-05-31 Janssen Sciences Ireland Uc Water suspensions TMC278
US20080081064A1 (en) * 2006-09-28 2008-04-03 Surmodics, Inc. Implantable Medical Device with Apertures for Delivery of Bioactive Agents
CL2008000746A1 (es) 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
EP2175857B1 (en) 2007-07-12 2013-09-11 Janssen R&D Ireland Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2009046299A2 (en) 2007-10-04 2009-04-09 Boston Scientific Scimed, Inc Implantable drug depot for intrathecal drug delivery system for pain management
US20110257111A1 (en) * 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives

Also Published As

Publication number Publication date
CY2016049I1 (el) 2017-07-12
NO2016025I1 (enrdf_load_stackoverflow) 2016-12-20
FI1663240T4 (fi) 2023-04-25
US20170100398A1 (en) 2017-04-13
NO2014031I2 (no) 2014-12-18
CY2015039I1 (el) 2016-08-31
US20190216807A1 (en) 2019-07-18
HUS1600059I1 (hu) 2017-02-28
LTC1663240I2 (lt) 2022-05-25
AP2109A (en) 2010-02-26
IL173438A0 (en) 2006-06-11
AU2014203484B2 (en) 2016-09-29
CA2537095A1 (en) 2005-03-10
JP2012051915A (ja) 2012-03-15
JP5507791B2 (ja) 2014-05-28
FR15C0072I1 (enrdf_load_stackoverflow) 2015-04-12
HRP20150798T1 (hr) 2015-09-11
PL1663240T3 (pl) 2015-10-30
BE2015C053I2 (enrdf_load_stackoverflow) 2023-12-14
EP1663240B1 (en) 2015-04-22
PL1663240T5 (pl) 2024-02-26
FR15C0071I1 (enrdf_load_stackoverflow) 2015-04-12
NL300781I2 (enrdf_load_stackoverflow) 2016-04-19
US20080200435A1 (en) 2008-08-21
LTPA2016044I1 (lt) 2017-01-10
NO2014032I1 (no) 2015-01-05
HK1092698A1 (en) 2007-02-16
FR16C1022I1 (fr) 2017-02-03
AU2011201123B2 (en) 2013-10-10
EP1663240B2 (en) 2023-03-01
AU2016210733A1 (en) 2016-08-25
EP1663240A1 (en) 2006-06-07
JP2015044839A (ja) 2015-03-12
CN101060844A (zh) 2007-10-24
US20100029591A1 (en) 2010-02-04
FR16C1024I1 (fr) 2017-02-03
NZ545306A (en) 2009-11-27
NO334877B1 (no) 2014-06-23
AU2014203484A1 (en) 2014-07-17
IL173438A (en) 2012-03-29
AU2004268390B2 (en) 2011-03-31
LTPA2016045I1 (lt) 2017-01-10
NL300768I2 (nl) 2023-08-09
US20220008417A1 (en) 2022-01-13
NO20061374L (no) 2006-03-27
AU2019200813A1 (en) 2019-02-28
KR20060090658A (ko) 2006-08-14
AU2011201123A1 (en) 2011-04-07
CY2015038I1 (el) 2016-08-31
MXPA06002437A (es) 2006-06-20
HUS1500052I1 (hu) 2016-03-29
JP5820045B2 (ja) 2015-11-24
CY2016049I2 (el) 2017-07-12
LU92853I2 (fr) 2015-12-21
JP2007520443A (ja) 2007-07-26
AP2006003551A0 (en) 2006-04-30
IL213104A0 (en) 2011-07-31
MY169670A (en) 2019-05-08
CY2015040I1 (el) 2016-08-31
NO2014030I2 (no) 2014-12-18
US20150283135A1 (en) 2015-10-08
US20140349971A1 (en) 2014-11-27
NL300768I1 (enrdf_load_stackoverflow) 2015-12-16
IL213104A (en) 2016-02-29
LU92855I2 (fr) 2015-12-21
HUS1600058I1 (hu) 2017-02-28
FR15C0073I2 (fr) 2016-02-12
FR15C0071I2 (fr) 2016-02-12
NO2016026I1 (no) 2016-12-20
HRP20150798T4 (hr) 2023-06-09
CY2016048I2 (el) 2017-07-12
CY2015040I2 (el) 2016-08-31
CY2016048I1 (el) 2017-07-12
CN101060844B (zh) 2012-01-04
NO2014030I1 (no) 2015-01-05
US20200171027A1 (en) 2020-06-04
US20180228800A1 (en) 2018-08-16
WO2005021001A1 (en) 2005-03-10
NO2014032I2 (no) 2014-12-18
CA2537095C (en) 2012-05-29
US8841310B2 (en) 2014-09-23
HUS1500053I1 (hu) 2016-03-29
NO2014031I1 (no) 2015-01-05
HUS1500054I1 (hu) 2016-03-29
LU92854I2 (fr) 2015-12-21
AU2004268390A1 (en) 2005-03-10
NL300781I1 (enrdf_load_stackoverflow) 2016-04-19
AU2016210733B2 (en) 2018-11-08
CY2015039I2 (el) 2016-08-31
FR15C0072I2 (fr) 2019-05-17
CY2015038I2 (el) 2016-08-31

Similar Documents

Publication Publication Date Title
FR15C0073I1 (enrdf_load_stackoverflow)
BE2013C075I2 (enrdf_load_stackoverflow)
BE2013C070I2 (enrdf_load_stackoverflow)
BE2013C067I2 (enrdf_load_stackoverflow)
BE2013C038I2 (enrdf_load_stackoverflow)
BE2013C036I2 (enrdf_load_stackoverflow)
BE2011C030I2 (enrdf_load_stackoverflow)
JP2004000609A5 (enrdf_load_stackoverflow)
JP2003301702A5 (enrdf_load_stackoverflow)
BE2013C034I2 (enrdf_load_stackoverflow)
JP2004078884A5 (enrdf_load_stackoverflow)
ECSDI034803S (enrdf_load_stackoverflow)
BE2012C053I2 (enrdf_load_stackoverflow)
DE602004016096D1 (enrdf_load_stackoverflow)
JP2004211697A5 (enrdf_load_stackoverflow)
JP2004127235A5 (enrdf_load_stackoverflow)
JP2004006829A5 (enrdf_load_stackoverflow)
JP2004162913A5 (enrdf_load_stackoverflow)
JP2004001482A5 (enrdf_load_stackoverflow)
JP2003269218A5 (enrdf_load_stackoverflow)
JP2004215087A5 (enrdf_load_stackoverflow)
AU2002362930A1 (enrdf_load_stackoverflow)
AU2002359010A1 (enrdf_load_stackoverflow)
AU2002253451A1 (enrdf_load_stackoverflow)
AU2002345911A1 (enrdf_load_stackoverflow)